Background. We performed quantitative real-time polymerase chain reaction (Q-PCR) to monitor the evolution of Brucella melitensis DNA load from initial diagnosis through post-therapy follow-up in patients with brucellosis.
Real-time PCR appears to be a more sensitive and specific detector of Brucella species than conventional methods of detection, including blood culture and serological tests. Moreover, compared with conventional PCR, real-time PCR facilitates quantification of nucleic acids, as well as automation and computerization of data. It has also been recognized as an outstanding tool in molecular diagnostic testing [5] [6] [7] . Real-time PCR assays have detected Brucella genus [8] and Brucella species [9] [10] [11] using pure culture Brucella DNA, and several reports of genus-specific real-time PCR assays of human specimens have recently been published [12] [13] [14] . Although these studies performed qualitative detection of Brucella species, none of them have quantified the bacterial DNA load in patients with brucellosis throughout different stages of the disease.
The aim of this study was to develop a quantitative- real-time PCR (Q-PCR) assay specific for Brucella melitensis DNA load measurement and to evaluate the evolution of the bacterial DNA load from the time of diagnosis through posttherapy follow-up in patients with brucellosis. On the basis of real-time fluorometric quantification of PCR products, we performed PCR using the ultra-rapid LightCycler system (Roche Diagnostics). The use of a single exonuclease hydrolysis probe for detection of PCR products in this assay ensured high specificity.
MATERIALS AND METHODS
Bacteria species and strains. The strains of Brucella species used in this study were kindly supplied by the Centro de Investigació n y Tecnología Agroalimentaria (Aragó n, Spain). Bacteria that were phylogenetically and serologically related to Brucella species were provided by Colecció n Española de Cultivos Tipo (Valencia, Spain) and the Department of Microbiology at the University of Navarra (Pamplona, Spain). The different species used are listed in table 1.
Patients and clinical specimens. This is an observational study of 18 patients with brucellosis that monitored the B. melitensis DNA load in blood from initial diagnosis through post-therapy follow-up. Because 7 patients relapsed during the follow-up phase, a total of 25 brucellosis episodes were monitored. Subjects were admitted to the study from January 2002 to November 2005 and received a diagnosis and treatment at either the Hospital of Hellin (Albacete, Spain) or the University Hospital of Albacete (Albacete, Spain). A total of 180 peripheral blood samples were obtained. A minimum of 3 samples-1 at diagnosis, at least 1 during antibiotic therapy and 1 during the post-therapy follow-up period-were obtained per patient. Routine Q-PCR, blood cultures, and serological and clinical evaluations were performed for each of the 180 samples.
Because patients were admitted to the study during a period of ∼4 years, treatment regimens were not homogeneously designed; rather, regimens were dependent on patients' symptoms and/or focal complications and on their involvement in other ongoing trials. Seven of the patients participated in a pilot study in which a single agent, doxycycline, was administered for 60 days. It has been shown that there is no statistically significant difference in treatment outcome between doxycycline administered as monotherapy for 6 weeks and the standard regimen of doxycycline plus rifampin [15] . The remaining 11 patients were treated with a combination of antibiotics. The post-treatment phase varied from 28 to 842 days, according to the continuity of patient visits to the clinic. Relapse was defined as the reappearance of a positive blood culture result during the posttherapy period and/or signs and symptoms of brucellosis infection. Treatment for the 7 patients who experienced relapse was as follows: 3 (42.9%) received a combination of doxycycline plus streptomycin, 3 (42.9%) received doxycycline plus gentamicin, and 1 pregnant female (14.2%) was treated with rifampin.
Analysis of the evolution of the bacterial DNA load from initial diagnosis through post-therapy follow-up was performed separately for 2 groups of patients: the 11 subjects who did not relapse in this study (hereafter referred to as "nonrelapse patients") and the 7 subjects who relapsed during follow-up (hereafter referred to as "relapse patients"). Comparisons were made of the bacterial DNA load in blood samples between the 2 groups during the initial treatment phase and the follow-up period.
Control blood samples were obtained from 30 healthy donors. The study was approved by the institutional review board at each center, and informed consent was obtained from all patients.
Blood culture and serological methods. Two or 3 blood cultures were processed for each specimen with a Bactec 9050 system (Becton Dickinson) according to the usual techniques. Identification of Brucella species was made according to standard microbiological techniques [16] . All of the isolated strains were sent to Centro de Investigació n y Tecnología Agroalimentaria (Zaragoza, Spain) for definitive identification and biotyping. All isolates were identified as B. melitensis biotype 3. Standard tube agglutination and Coombs tests were performed as described elsewhere [17] .
DNA extraction from bacteria strains and clinical specimens. Cultures of each bacteria strain were washed from agar plates with sterile, high-purity water (Milli-Q, Millipore SA), were incubated at 100ЊC for 30 min, and underwent 2 centrifugations at 14,000 g for 5 min. The supernatant was transferred to a fresh tube and was centrifuged at 14,000 g for 1 min. Peripheral blood samples from patients and control subjects were collected in EDTA. All samples were aliquoted and stored at Ϫ20ЊC until tested. DNA was isolated with an UltraClean DNA-BloodSpin kit (Mo Bio Laboratories), in accordance with the manufacturer's instructions. All of the final DNA concentrations and purities were measured spectrophotometrically.
Primers and TaqMan probe. The forward primer sequence (EFQ1) was 5 -TGTTTCGGCTCAGAATAATCC A-3 , and the reverse primer sequence (ERQ2) was 5 -GCATGCGCTATGA-TCTGGTTA C-3 . The TaqMan probe sequence (STqME) was 5 -6-carboxy-fluorescein (FAM)-AGCTTACCCGCCAATCT-TCGCCCXT-3 ("X" is 6-carboxy-tetramethyl-rhodamine [TAMRA] , and the 3 -ends are blocked with a phosphate group to prevent extension of probe in the PCR reaction).
These primers produce an amplicon of 251 base pair (bp) that spans a region of the B. melitensis genome (GenBank accession number AE009555) and the IS711 insertion element. We used the same gene described elsewhere [9, 11] to detect B. melitensis DNA, but we used different primers and probe. The fluorescent reporter molecule at the 5 -end of the TaqMan probe was FAM, and the quenching molecule was TAMRA. The theoretical specificity of the primers and probe was determined by comparison with the GenBank database using the Basic Local Alignment Search Tool (BLAST) [18] .
Template preparation for standard curve. The B. melitensis fragment was amplified using primers EFQ1 and ERQ2 and inserted into pGEM-T Easy Vector Systems (Promega), in accordance with the manufacturer's instructions. After plasmid preparation, the DNA concentration was determined with a spectrophotometer at 260 nm, and the corresponding copy number was calculated. The standard curve was constructed by plotting the logarithmic values of a known number of bacterial copies versus the cycle threshold (C t ) value.
Light Cycler Q-PCR assays. To each LightCycler glass capillary, we added 20 mL of PCR mixture containing 400 nM of primers, 100 nM of TaqMan probe, 400 ng of human DNA, 6 mM of MgCl 2 (final concentration), and 4mL of 5ϫ concentration solution of LightCycler-FastStart DNA master hybridization probes (Roche Diagnostics). Cycling conditions consisted of initial denaturation at 95ЊC for 10 min followed by 45 cycles at 95ЊC for 10 s, at 60ЊC for 15 s, and at 72ЊC for 15 s. The fluorescence was acquired once every cycle after the extension step using F1/F2 filters, and the number copies of B. melitensis per milliliter of blood was calculated from the standard curve. Negative and positive controls were also included in each Q-PCR run. Collected samples were randomly analyzed in triplicate in a single-blinded way. The Q-PCR result was considered positive when at least 1 of the replicates was positive.
Statistical analysis. The x 2 test or Fishers' exact test were used to compare categorical variables between the different groups, and the Student's t test or the Wilcoxon rank-sum test were used to compare continuous variables. A P value of !.05 was considered to be statistically significant.
RESULTS

Specificity and sensitivity of the Q-PCR assay.
The analytical sensitivity was performed with a linear assay over 7 orders of magnitude (from 150 ng to 1 fg). B. melitensis-specific assay could detect as little as 15 fg of DNA. This is equivalent to 1 genome copy of the original bacteria stock from which the DNA was extracted (assuming that 10-15 fg of DNA is equivalent to 1 genome).
Amplification of 7-fold serial dilutions of a plasmid with the cloned fragment of 251 bp from Rev 1 strain of B. melitensis revealed a linear detection range of 10 7 -10 2 copies per reaction mixture, with an R 2 value of 0.99 and a PCR efficiency of 2. The correlation of the C t value and plasmid copy number (copy no.) was:
. Therefore, from C p Ϫ3.260 ϫ log (copy no.) + 37.59 t this standard curve, we determined the number of bacteria copies present in 400 ng of human genomic DNA by interpolation of the C t value of each Q-PCR assay to the standard curve.
The Q-PCR assay was 100% specific. Five different species of the genus Brucella, strains phylogenetically related to Brucella species, and gram-negative bacteria showing serological crossreactions with Brucella species all negative results with Q-PCR ( Duration of symptoms prior to diagnosis was 7-60 days (median, 15 days). The sensitivity of Q-PCR, Coombs test, blood culture, and standard tube agglutination at the moment of initial diagnosis were 100%, 100%, 94%, and 77%, respectively ( ) .
Although all 18 patients demonstrated resolution of symptoms halfway through the treatment period, 9 culture-positive blood samples were obtained during this phase from 7 patients (4 nonrelapse patients and 3 relapse patients). However, at the conclusion of treatment, cultures of all blood samples were negative. Following initial treatment and recovery, 7 of the 18 patients (3 females and 4 males) eventually experienced symptomatic relapses between 11 and 225 days (median, 63 days) after the conclusion of therapy. Three of these patients had positive blood culture results, and 4 experienced clinical relapse only. The sensitivity of Q-PCR for the relapse patients was 100% versus 43% for blood culture, 86% for the Coombs test, and 29% for standard tube agglutination ( ), respectively. P p .014 Quantification of B. melitensis DNA load in clinical specimens. All blood samples obtained from 30 healthy donors who were our control subjects were negative for B. melitensis. Therefore, the specificity of our Q-PCR assay was 100%.
Analysis of the evolution of the bacterial DNA load from initial diagnosis through post-therapy follow-up was separated into 2 groups: the nonrelapse group (11 patients) and the relapse group (7 patients). A comparison of the quantity of bacteria DNA between groups from initial diagnosis to end of follow-up revealed no statistically significant differences (P 1 ). The evolution of the bacterial DNA load in nonrelapse .05 patients is shown in figure 1 . At initial diagnosis, the mean B. melitensis DNA load (‫ע‬SD) for the 11 patients was 1171 ‫ע‬ copies/mL (range, 7-4528 copies/mL). During the treat-1662 ment period, we observed a dramatic decrease in the bacterial DNA load ( copies/mL; range, 0-35 copies/mL) for the 12 ‫ע‬ 16 first 3 weeks, coinciding with disappearance of symptoms. This decrease was followed by a mild increase from the fourth to the seventh week, with a mean bacterial DNA load of 62 ‫ע‬ copies/mL (range, 0-256 copies/mL). At the completion of 106 treatment, the Q-PCR results for 7 patients (63.6%) remained positive, with a mean bacterial DNA load of copies/ 11 ‫ע‬ 12 a We were unable to obtain a sample on completion of therapy for 1 patient who received combination treatment and relapsed 9 months after the initial brucellosis episode.
mL (range, 0-27 copies/mL). Shortly after the conclusion of treatment, we observed another mild increase in the bacterial DNA load ( copies/mL; range, 0-250 copies/mL) until 31 ‫ע‬ 69 the fourth month after therapy, after which it gradually decreased during the remainder of the follow-up period to 4 ‫ע‬ copies/mL (range, 0-15 copies/mL). The Q-PCR results of 3 8 nonrelapse patients remained positive at the conclusion of the study. Evolution of the bacterial DNA load in relapse patients is shown in figure 2 .
During the initial treatment phase, relapse patients presented a bacterial DNA load curve similar to that of nonrelapse patients. At initial diagnosis, the mean bacterial DNA load (‫ע‬SD) for the 7 patients in the relapse group was copies/ 1706 ‫ע‬ 1872 mL (range, 7-4982 copies/mL). The bacterial DNA load decreased to copies/mL (range, 0-23 copies/mL) shortly 12 ‫ע‬ 16 after the initiation of antibiotic therapy and rose again slightly after the fourth week of treatment to copies/mL 77 ‫ע‬ 135 (range, 0-279 copies/mL). At the completion of therapy, the mean bacterial DNA load dropped to copies/mL 10 ‫ע‬ 12 (range, 3-24 copies/mL), and the Q-PCR results of 2 patients (28.6%) remained positive.
During the follow-up phase of the study, patients experienced relapse at varying times. The 2 post-treatment peaks observed in figure 2 correspond to 3 episodes of microbiological relapse. At diagnosis, the mean bacterial DNA load ‫ע(‬ SD) of the 7 patients in the relapse group was copies/mL 1103 ‫ע‬ 1932 (range, 3-4920 copies/mL). In the relapse group, the mean bacterial DNA load ‫ע(‬ SD) was copies/mL 2540 ‫ע‬ 2404 (range, 113-4920 copies/mL) for those with microbiological relapse and copies/mL (range, 3-88 copies/mL) for 26 ‫ע‬ 41 those with clinical relapse ( ). At the conclusion of the P p .033 follow-up phase, the Q-PCR results of 4 relapse patients remained positive. We were only able to monitor 6 patients for 110 months after therapy, 3 of whom continued to have positive Q-PCR results, albeit with low bacterial DNA loads (range, 13-22 copies/mL). Two of the 3 patients with long-term positive Q-PCR results were relapse patients with a variety of focal complications. The third patient, a nonrelapse patient, remained asymptomatic for the duration of the 24-month posttherapy follow-up.
The current study did not aim to analyze the influence of monotherapy versus combination drug therapy on treatment outcome, as measured by the rate of relapse and B. melitensis DNA load. Nonetheless, we observed that 71.4% of patients (5 of 7) who received monotherapy had positive Q-PCR results at the cessation of treatment, of whom 40% (2 of 5) experienced relapse (table 3 ). Only 40% of the patients (4 of 10) who received combination therapy had positive Q-PCR results after treatment, none of whom experienced relapse, which implies that combination treatment is more effective. However, of the 60% of the patients (6 of 10) who received combination therapy had a bacterial DNA load of 0 copies/mL after the completion of therapy, and 50% (3 of 6) experienced relapse. One additional patient from the group receiving combination therapy experienced relapse; we were not able to obtain a blood sample from this patient after the completion of treatment. In summary, 4 of the 7 patients who experienced relapse came from the combination therapy group. In terms of comparing the bacterial DNA loads among monotherapy and combination therapy recipients during treatment, no statistically significant differences were found ( ). P 1 .05
DISCUSSION
Previous studies using Q-PCR have occasionally detected Brucella species DNA in patients after the completion of therapy; this finding is usually linked to clinical relapse [19, 20] . In the current study, by using Q-PCR, not only did we consistently detect B. melitensis DNA in blood during antimicrobial therapy and post-treatment follow-up in relapse and nonrelapse patients, but we were also able to quantify the bacterial DNA load. Our findings may have diagnostic, pathogenic, and therapeutic implications.
With respect to Q-PCR as a diagnostic tool for brucellosis, our results demonstrated 100% sensitivity and 100% specificity for both initial infection and relapse episodes. Nonetheless, the control group included only healthy blood donors who had neither clinical nor serological evidence of brucellosis and had no epidemiological exposure to the bacteria. Therefore, new studies including patients with other infectious diseases, patients with previous episodes of brucellosis, and healthy persons exposed to Brucella species are needed to further evaluate the specificity of the assay.
Regarding the pathogenic course of brucellosis, we were able to obtain a long-term picture of the evolution of bacterial DNA in blood, possibly reflecting the underlying dynamics of the disease (figures 1 and 2) . The most significant characteristic of the infections of both relapse and nonrelapse patients in this study is the persistence of B. melitensis DNA load in the blood. By the end of treatment, despite apparent recovery from infection, 50% of patients (7 relapse and 2 nonrelapse patients) had low-level positive Q-PCR results. At the conclusion of follow-up, almost 40% of patients (4 relapse and 3 nonrelapse patients), most of whom were asymptomatic, continued to have low bacterial DNA loads. In reference to bacterial DNA load curves, aside from a sharp decrease in bacterial DNA load after initiating treatment in both groups of patients, we observed a distinct rise and fall in thenumber of DNA copies per milliliter of blood halfway through treatment among relapse and nonrelapse patients, and again during follow-up among nonrelapse patients. This pattern suggests a complex interaction between antibiotic suppression, bacteria survival mechanisms, and host immune response to the disease. During treatment, there were no significant differences between relapse and nonrelapse patients with respect to evolution or bacterial DNA load. Thus, monitoring bacterial DNA loads in patients undergoing antibiotic therapy for brucellosis may not facilitate prediction of relapse.
Other studies using conventional PCR have documented Brucella species DNA detection in symptomatic and asymptomatic post-treatment brucellosis patients [14, 19, 21] . Morata et al. [19] described an asymptomatic individual who presented with residual bacterial DNA 6 months after therapy. The result was considered to be false positive. Similarly, a study by QueipoOrtuño et al. [14] described 2 asymptomatic subjects with positive PCR results. In our study, we consistently obtained higher numbers of samples that were positive by Q-PCR than the studies mentioned above, perhaps because the sensitivity of Q-PCR is greater than that of conventional PCR.
Persistent bacterial DNA load detected by PCR has also been reported in human infections caused by Borrelia burgdorferi [22, 23] and Mycobacterium tuberculosis [24] . Although positive Q-PCR results do not prove active infection by living bacteria, the persistence of DNA raises the possibility of latent infection inside the cells. It has been shown that Brucella species can survive inside macrophage cells, eluding host immune response and impeding effective antibiotic action [1] . Interestingly, 4 patients in our study who had negative Q-PCR results at the finalization of treatment relapsed, which suggests that, although B. melitensis DNA was not present in blood, it may have been surviving intracellularly. In addition, Spink and Bradley [25] describe an experimental model mouse infected with B. melitensis, from which Brucella colony-forming units were recovered from spleen tissue long after the conclusion of antibiotic therapy.
Regarding the therapeutic implications of Q-PCR analysis, the patient's clinical context and the limitations of the technique must be taken into account when interpreting results. Many asymptomatic patients in our study had positive Q-PCR results at the cessation of treatment and during follow-up without experiencing relapse. Therefore, a positive Q-PCR result from an asymptomatic patient recently treated with appropriate antibiotic therapy does not necessarily warrant further treatment. However, a positive Q-PCR result from an untreated, symptomatic patient likely indicates necessity for antibiotic therapy. Conversely, because of the sensitivity of the technique, a negative Q-PCR result probably rules out active brucellosis infection, but does not exclude the possibility of eventual relapse.
In conclusion, our data suggest that brucellosis may be a chronic, relapsing disease comparable with those caused by intracellular pathogens such as M. tuberculosis, in which the bacteria persist during and after therapy, despite appropriate antibiotic treatment and a good host response. To better understand the course of brucellosis, the significance of the persistence of B. melitensis DNA in patients with brucellosis, and the nature of relapse, prospective studies involving larger, more homogeneously treated persons should focus on monitoring the long-term post-therapy course of the disease.
